April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Correlation Between Vitreous Haze and Visual Acuity in Patients Treated With LX211 (LuveniqTM/Voclosporin Oral Capsule) in an Active Uveitis Affecting the Posterior Segment
Author Affiliations & Notes
  • D. Callanan
    Texas Retina Associates, Arlington, Texas
  • Luminate Study Group
    Texas Retina Associates, Arlington, Texas
  • Footnotes
    Commercial Relationships  D. Callanan, Bausch & Lomb, C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 6377. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. Callanan, Luminate Study Group; Correlation Between Vitreous Haze and Visual Acuity in Patients Treated With LX211 (LuveniqTM/Voclosporin Oral Capsule) in an Active Uveitis Affecting the Posterior Segment. Invest. Ophthalmol. Vis. Sci. 2010;51(13):6377.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Assess correlation between Ocular Inflammation and Vision as measured by Vitreous Haze and BCVA in patients treated with LX211 (LuveniqTM/voclosporin oral capsule) for active posterior non-infectious uveitis.

Methods: : Study LX211-01 assessed the response of LX211 in patients with active posterior-segment disease with mean change in vitreous haze as the primary endpoint. BCVA was assessed as a safety parameter. Vitreous haze was measured by the SUN Working Group ordinal scale and vision was assessed using ETDRS. Change in inflammation versus change in visual acuity score within the 6-month study period was plotted.

Results: : 218 patients were enrolled in the LX211-01 study. Patients in the LX211-01 protocol had a mean vitreous haze (VH) score of 2.1 at baseline; mean decrease in VH in the 0.4 mg/kg BID LX211 treatment group at Week 24 was -1.1, statistically significant compared to placebo. Visual Acuity in the LX211-01 was preserved in all treatment groups with mean change in visual acuity from baseline ranging from -0.5 in the 0.2 mg/kg BID LX211 treatment group to +1.5 in the 0.6 mg/kg BID LX211 dose group. Changes in VH ranged from -3.0 and +2.0. Change in VH of -3.0, -2.0, -1.0, 0.0, +1.0, +2.0 correlated to a mean change in BCVA of 2.6, 6.0, 3.1, 0.8, -17.7, -5.0, respectively.

Conclusions: : A decline in vitreous haze was associated with minor improvement in vision while an increase in inflammation was associated with a major decrease in vision. Control of inflammation is paramount to preserve visual acuity in noninfectious uveitis patients.

Clinical Trial: : www.clinicaltrials.gov NCT00404885

Keywords: uveitis-clinical/animal model • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×